Aims/hypothesis. Proinsulin C-peptide is generally believed to be inert without any appreciable biological functions. However, it has been shown to modulate a variety of cellular processes important in the pathophysiology of diabetic complications. We therefore investigated the ability of C-peptide to stimulate intracellular signalling pathways in kidney proximal tubular cells, the altered activation of which may possibly be related to the development of diabetic nephropathy. Methods. Extracellular signal-regulated kinase (ERK) and Akt phosphorylation were evaluated by western blotting. ERK activity was measured by in vitro kinase assay. Intracellular Ca 2+ was evaluated by confocal imaging. The membrane and cytosol-associated fractions of protein kinase C (PKC) isoforms were evaluated by western blotting. Proliferation was assessed by thymidine incorporation assay. Results. Using the opossum proximal tubular kidney cell line as a model, we demonstrated that at high picomolar to low nanomolar concentrations, C-peptide stimulates extracellular signal-regulated mitogen-activated kinase (3.3±0.1-fold over basal at 3 minutes) and phosphatidylinositol 3-kinase (4.1±0.05-fold over basal at 5 minutes). ERK activation was attenuated by pre-treatment with a PKC inhibitor and abolished by pertussis toxin. Elevations of intracellular [Ca 2+ ] are seen in response to 5 nmol/l C-peptide with consequent activation of PKC-α. Pre-treatment with pertussis toxin abolished PKC-α. C-peptide is also a functional mitogen in this cell type, stimulating significantly increased cell proliferation. Proliferation was attenuated by wortmannin and pertussis toxin pretreatments. None of these effects is reproduced by scrambled C-peptide. Conclusions/interpretation. This study provides evidence that C-peptide, within physiological concentration ranges, stimulates many signalling pathways in opossum kidney cells.
Introduction
Proinsulin connecting peptide (C-peptide) is an enzymatic cleavage product derived from proinsulin during the biosynthesis of insulin [1] . Insulin and C-peptide are stored together within the secretory granules of pancreatic beta cells, being eventually released simultaneously and in equimolar amounts into the portal circulation [2] . C-peptide forms a linker between the A and B chains of insulin, facilitating correct folding and thus the establishment of disulfide bonds between adjacent cysteine residues [3] . Early after the discovery of C-peptide, workers attempted to delineate a role for C-peptide in the regulation of glucose homeostasis [4, 5, 6] . No such role could be found, encouraging the traditional belief that C-peptide is a biologically inert molecule.
Accumulating evidence, however, has begun to challenge this view by suggesting that C-peptide plays a role in experimental and clinical diabetes. The infusion of C-peptide into patients with Type 1 diabetes over the short term (hours), in addition to the administration of insulin, ameliorates a variety of associated renal functional abnormalities [7] . Similarly, the more prolonged administration of C-peptide (months) is associated not only with improved renal function, but also enhanced autonomic and sensory nerve function [8, 9, 10, 11] . Characteristic myocardial perfusion and limb blood flow changes observed in patients with Type 1 diabetes are also reversed by C-peptide [11, 12] . No effects of C-peptide infusion on any of these parameters have ever been demonstrated in healthy non-diabetic control subjects [8, 9, 10, 11] .
At the cellular level various effects of C-peptide have now been described. Activation of Na + /K + -ATPase occurs in numerous nephron segments in response to C-peptide stimulation, together with increased intracellular Ca 2+ concentrations ([Ca 2+ ] i ) in proximal tubular cells [13, 14, 15, 16] . Recently Kitamura et al. [17] demonstrated C-peptide-mediated stimulation of a kinase cascade in Swiss 3T3 fibroblasts involving mitogen-activated protein kinases (MAPK), protein kinase C (PKC) and phosphoinositide-3-kinase (PI3-K). Specific cell membrane binding sites for C-peptide have recently been identified in renal tubular cells, skin fibroblasts and saphenous vein endothelial cells. Abolition of this binding by pertussis toxin (PTX) was observed, suggesting the involvement of a G-protein coupled receptor (GPCR). The calculated association rate constant (K ass ) of this receptor was about 3 nmol/l, which suggests that under normal physiological conditions it is probably fully occupied, possibly explaining the absence of C-peptide effects in normal subjects [18, 19] .
Diabetic nephropathy remains a serious complication of diabetes, and is characterised initially by renal growth. Hypertrophy of glomerular and tubular cells is prominent, together with thickening of basement membranes, but hyperplasia does not occur [20, 21, 22] . Later, matrix components accumulate in the glomerulus and tubulo-interstitium with progressive sclerosis. Tubular atrophy with almost complete loss of proximal tubular cells (PTC) is evident, a clear sign of major disturbances in growth and survival of this cell type. Interestingly, the pathogenesis of nephropathy does not seem to be substantially different in Type 1 and Type 2 diabetes [23, 24, 25] .
Much attention has been given to signal transduction pathways activated in response to the persistent homeostatic disturbances in diabetes that may initiate and/or propagate diabetic renal pathophysiology. Activation of PKC in the kidney occurs within days of the onset of experimental diabetes [26] , and this may in turn stimulate phospholipase A2, leading to the release of membrane-bound arachidonate [26, 27] . Another consequence of renal PKC activation is stimulation of MAPK [28] . The activation of MAPK in glomeruli obtained from rats with streptozotocin-induced diabetes and in mesangial cells grown in high glucose concentrations is mediated by PKC and contributes crucially to cell hypertrophy [29] .
The precise role of C-peptide, or the lack thereof, in the modulation of these signalling pathways in diabetes and in the pathogenesis of diabetic nephropathy remains uncertain. Therefore, in view of our long-standing interest in renal tubular disease and the body of literature supporting a physiological role for C-peptide, we examined signalling and functional roles for C-peptide in the kidney. Our primary aim was to determine whether C-peptide has the capacity to signal in PTC, focusing especially on pathways involved in cell growth and the potential development of diabetic nephropathy. We used opossum kidney (OK) cells, an immortalised kidney PTC cell line [30] that retains many characteristics of the proximal tubule [31] . Many typical proximal tubular functions such as parathyroid hormone responses and endocytic uptake of proteins have been investigated using this cell type [32, 33] .
Materials and methods
Materials. Human 31 amino acid (aa) C-peptide and a 31 aa scrambled C-peptide were generously provided by Dr J. Wahren (Karolinska Institute, Stockholm, Sweden). These peptides were prepared as 250 µmol/l stock solutions in 50 mmol/l glacial acetic acid, and stored at −20°C. All tissue culture media and plasticware were from Invitrogen Life Technologies (Paisley, UK) and general laboratory chemicals were from Sigma (Poole, UK) unless otherwise stated. Wortmannin, PTX and Ro-31-8220 were from Calbiochem (Nottingham, UK). The extracellular signal-regulated MAP kinase (ERK) substrate, a peptide (RRELVEPLTPSGEAPNQALLR) derived from the cytoplasmic tail of the epidermal growth factor receptor, was synthesised by the Protein and Nucleic Acid Chemistry Laboratory (University of Leicester, UK). Rabbit polyclonal anti-ERK-1 and antiphospho-ERK1/2 were obtained from Santa Cruz Biotechnology (Santa Cruz, Calif., USA). Sheep monoclonal anti-Akt1/PKBα and anti-phospo-Akt1/PKBα were from Upstate Biotechnology (Milton Keynes, UK). Anti-PKC isoforms were from Transduction Laboratories (San Diego, Calif., USA). Protein A sepharose CL-4B was from Pharmacia Biotech (Uppsala, Sweden). We obtained γ- Cell culture. Opossum kidney cells were obtained from Dr J. Caverzasio (University Hospital, Geneva, Switzerland) and used between passages 72-87. Cells were maintained in Dulbecco's modified Eagle's media-Ham's mix (DMEM-F12), supplemented with 10% FCS, 2 mmol/l L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 10 mmol/l HEPES. In all experiments cells were serum-starved overnight before being subject to agonist stimulation to ensure as far as possible that cells were not exposed to mitogenic agents or C-peptide derived from FCS.
Determination of ERK and Akt activation by western blotting of phospho-ERK and phospho-Akt. Cells growing in 6-well plates were stimulated with various concentrations of C-peptide or scrambled peptide in serum-free DMEM-F12 for various times. After stimulation, cells were rinsed with ice-cold PBS and then lysed in Laemmli buffer (60 mmol/l Tris, pH 6.8, 10% glycerol, 2% SDS, 100 mmol/l dithiothreitol [DTT] and 0.01% bromophenol blue). Samples were separated by SDS-PAGE and then transferred to nitrocellulose membranes. Membranes were blocked with a 5% (w/v) solution of dried milk powder in TTBS (20 mmol/l Tris base, 100 mmol/l NaCl and 0.05% Tween 20, pH 7.5) and immunoblotted using antisera against phosphorylated ERK or phosphorylated Akt. To check the uniformity of loading, blots were stripped and re-probed with antisera to total (phospho-and non-phospho ERK-1) ERK or total Akt. In all cases, primary antibodies were visualised using peroxidase-conjugated secondary antibodies and enhanced chemiluminescence (Amersham). Immunoblots were quantitated using Scion Image analysis software (version 4.0.2; Scion, Frederick, Md., USA).
Determination of ERK activity by in vitro kinase assay. ERK activity in OK cells after treatment with test agents was measured using an in vitro kinase assay, in essence as previously described [34] . Briefly, confluent monolayers of OK cells were grown in 6-well plates. After stimulation, the cells were washed once with ice-cold PBS and then solubilised with icecold lysis buffer (20 mmol/l Tris-HCl, pH 8.0, 0.5% Nonidet P-40, 250 mmol/l NaCl, 3 mmol/l EDTA, 3 mmol/l EGTA, 1 mmol/l phenylmethansulfonylfluoride [PMSF], 2 mmol/l Na 3 VO 4 and 1 mmol/l DTT). The lysates were clarified by 10 minutes of centrifugation at 14000 g at 4°C. Next rabbit polyclonal anti-ERK-1 antiserum (stock concentration 200 µg/ml) was added to give a final concentration of 2 µg/ml, and incubated for 120 min on ice. Immune complexes were incubated for 30 min at 4°C with 100 µl of a 15% (v/v) slurry of protein A-sepharose. Immunoprecipitates were then washed twice in 200 µl lysis buffer and twice in 200 µl kinase buffer (20 mmol/l HEPES, pH 7.2, 20 mmol/l β-glycerophosphate, 10 mmol/l MgCl 2 , 1 mmol/l DTT and 50 µmol/l Na 3 VO 4 ). An aliquot of 40 µl kinase buffer containing 20 µmol/l γ[ 32 P]-ATP (92.5 kBq/nmol) and 200 µmol/l of synthetic ERK peptide substrate was added to immunoprecipitates to initiate the kinase reaction. The reactions were terminated after 20 minutes by adding 10 µl of 25% (w/v) trichloroacetic acid. The mixtures were then centrifuged at 14000 g for 2 min and 40 µl of the supernatant spotted on to squares of P81 cation exchange paper (Whatman, Maidstone, UK). Papers were washed three times for 5 min in 0.5% (v/v) orthophosphoric acid, rinsed once with acetone and air-dried, after which radioactivity was determined by liquid scintillation counting. 2+ ] i . OK cells were plated on to sterile 25-mm diameter poly-D-lysine-coated glass cover slips and allowed to adhere for 24 h. Cells were incubated in Krebs buffer (10 mmol/l HEPES, 4.2 nmol/l NaHCO 3 , 11.7 mmol/l D-glucose, 1.18 mmol/l MgSO 4 ·7H 2 O, 1.18 mmol/l KH 2 PO 4 , 4.69 mmol/l KCl, 118 mmol/l NaCl, 1.29 mmol/l CaCl 2 ·2H 2 O, pH 7.4) containing 6 µmol/l fluo-3-acetoxymethyl ester (fluo-3-AM, Molecular Probes, Cambridge, UK). This was done at room temperature for 45 to 90 min. Cover slips were then mounted in a chamber on a heated stage of an Olympus 1x 70-SIF inverted microscope. The chamber was perfused with Krebs buffer (bath temperature 37°C), with or without C-peptide or scrambled C-peptide, at 5 ml per minute. The intracellular fluorescence, as an index of [Ca 2+ ] i , was determined by using an Ultraview confocal imaging system (Perkin Elmer). Cells were excited with a krypton/argon laser at 488 nm and emitted light was collected above 510 nm with a narrow-band pass filter.
Confocal imaging of [Ca

Determination of PKC activation by translocation assay.
The cytosol to membrane translocation of PKCα was determined by cell fractionation and western blotting as an index of activation as previously described [35] Proteins were separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted for PKCα, ε and ι as described above, using anti PKCα, ε and ι at 0.1, 0.5 and 0.5 µg/ml respectively. The nitrocellulose was subsequently stained using Ponceau-s (0.2% Ponceau-S and 3% TCA) to ensure equivalent protein loading and transfer.
Incorporation of [ 3 H]-thymidine.
Proliferation of OK cells in response to C-peptide was assessed by [ 3 H]-thymidine incorporation. Cells were plated in 24-well plates and grown to approximately 80% confluence. Serum-starved cells were exposed to various concentrations of C-peptide, 10% fetal calf serum or serum-free media as a control. After 22 h of incubation at 37°C, the culture medium was replaced with serumfree medium containing 37 kBq of [ 3 H]-thymidine. After a further 2 h of incubation, cells were washed with ice-cold PBS and fixed at 4°C in 50% methanol and 10% glacial acetic acid for 30 min, and then in 10% trichloroacetic acid for 10 min. Cells were then solubilised overnight in 100 mmol/l NaCl containing 0.1% SDS, after which [ 3 H]-thymidine incorporation was determined by standard liquid scintillation counting.
Data presentation and analysis. Data are presented as means ± SEM. Statistical analysis was by unpaired Student's t test for comparison between two experimental groups. For multiple comparisons, one-way ANOVA with Tukey's correction was used. Differences were considered significant at a p value of less than 0.05.
Results
Effect of C-peptide on activation of ERK-1 and -2.
Incubation of OK cells with C-peptide resulted in a time-and a concentration-dependent increase in phos-phorylated ERK (Fig. 1) . Phosphorylated ERK appeared rapidly after stimulation, displaying a peak and plateau. A maximal stimulation of 3.3±0.1-fold over basal occurred at 3 min, which fell to a plateau between 10 and 30 min. Phosphorylation of ERK increased 1.8±0.1-fold over the basal at C-peptide concentrations as low as 100 pmol/l, with maximal stimulation of 2.1±0.1-fold over basal occurring at 300 pmol/l. The phosphorylation of ERK-1 and -2 decreased progressively with concentrations of C-peptide above 300 pmol/l. Loading controls using total ERK-1 antisera demonstrated equivalent protein loading between lanes. Scrambled C-peptide did not affect phosphorylation of ERK-1 or ERK-2 (Fig. 1c) .
To confirm that C-peptide activated ERK in OK cells, we also examined ERK activity by immune complex in vitro kinase assay, using a synthetic peptide that corresponds to a portion of epidermal growth factor receptor as substrate. Figure 2 shows a concentration-dependent stimulation of ERK activity in response to C-peptide for 5 min. The concentration response is very similar to that observed in the phosphorylated ERK immunoblots, with maximal ERK activity (135±1%) relative to control being observed with 500 pmol/l C-peptide and declining thereafter. Scrambled C-peptide had no significant effect on ERK activity (Fig. 2a) . To determine the role of Gα i/o G-proteins in activation of ERK, cells were pre-incubated overnight with PTX, an agent that ADP-ribosylates and inhibits Gα i/o proteins. Pre-treatment of the cells with PTX entirely blocked the activation of ERK induced by C-peptide (Fig. 2b) . Similarly pre-treatment with the PKC inhibitor, bisindolylmaleimide (Ro-31-8220; 10 µmol/l, 30 min), also significantly attenuated C-peptide-induced ERK activity (Fig. 2b) . Pre-treatment with the PI-3 kinase inhibitor wortmannin (100 nmol/l, 30 min) had no significant effects on C-peptide-induced ERK activity (Fig. 2b) . PTX also abolished the ability of C-peptide to cause phosphorylation of ERK-1 and ERK-2 as detected by immunoblotting (Fig. 2c) .
Effect of C-peptide on Akt phosphorylation.
To investigate the effects of C-peptide on Akt activation in OK cells, western blot analyses with Akt-S473-phosphospecific antibodies were performed. C-peptide-evoked Akt stimulation was time-dependent. Significant Akt phosphorylation was apparent as early as 1 minute, with maximal stimulation of Akt phosphorylation to 4.1±0.05-fold over basal occurring after 5 minutes of exposure to C-peptide (Fig. 3) . Robust, concentrationdependent activation of Akt by C-peptide, with a substantial activation of Akt by 100 pmol/l C-peptide, was also observed. Maximal phosphorylation of Akt to 2.5±0.03-fold over the basal was observed with 5 nmol/l C-peptide. The total amount of Akt was not changed at any concentration of C-peptide tested (Fig. 3a, b) . Akt activation was not stimulated by scrambled C-peptide (Fig. 3c) .
To determine whether phosphorylation of Akt by Cpeptide was dependent on PI3-K activity, we examined the effect of the PI-3 kinase inhibitor wortmannin on Akt phosphorylation. We found that C-peptide-induced Akt phosphorylation was completely abolished by pretreatment of cells with wortmannin 100 nmol/l (Fig.3d) . Figure 4 depicts a representative field of cells viewed in real time by confocal microscopy. Figure 4c shows a graphical representation of the effects of Fig. 2 . Stimulation of extracellular signal-regulated kinase (ERK) activity by C-peptide but not scrambled C-peptide in opossum kidney cells. Activity was measured by in vitro kinase assay. a. Opossum kidney (OK) cells were treated with the indicated concentrations of C-peptide (squares) or scrambled C-peptide (circles) for 5 minutes and ERK activity measured. Results are percentages ± SEM (n=3) of negative control cells that were incubated with serum-free media. *p<0.05, **p<0.01, relative to controls. b. Effects of pertussis toxin (P), Ro-31-8220 (Ro) and wortmannin (W) on basal (hatched bars) and C-peptide-induced (black bars) ERK activity in OK cells. Unlabelled bars represent basal or C-peptide-induced ERK activity in the absence of inhibitors. OK cells were pre-treated with 100 ng/ml pertussis toxin for 18 h or with Ro-31-8220 (10 µmol/l) for 30 min or with wortmannin (100 nmol/l) for 30 min. Cells were then incubated with 1 nmol/l C-peptide for 5 min. The effect of phorbol dibutyrate (PDBU) is shown as a positive control. Results are percentages ± SEM (n=3) of control cells incubated with 1 nmol/l C-peptide alone. *p<0.05, relative to C-peptide alone. c. Pertussis toxin inhibits C-peptide-induced ERK phosphorylation detected by immunoblotting in OK cells. OK cells were pre-treated with 100 ng/ml pertussis toxin for 18 h and then incubated with 1 nmol/l C-peptide for 5 min. The blot is representative of three independent experiments C-peptide on [Ca 2+ ] i as fold increases in fluorescence intensity compared to basal levels. Cell 1 (Fig. 4c) exhibited an increase in fluorescence intensity of about 3.3-fold over basal, returning to basal within 1 min. Cell 2 (Fig. 4c) shows a more modest increase in fluorescence intensity (about 1.1 over basal), while cell 3 ( Fig.4c) 
Effect of C-peptide on intracellular
Effect of C-peptide on activation of PKC isoforms.
Using western blotting, we reliably detected the PKC isoforms -α, -ε, -ι in OK cells (Fig. 5a) . To examine the effects of C-peptide on PKC activity, we analysed C-peptide-induced translocation of these PKC isoforms from a cell cytosolic compartment to a membrane compartment by cell fractionation. Control experiments showed that treatment of OK cells with 1 µmol/l phorbol myristate acetate (PMA) for 5 min increased the amounts of PKC-α in the membrane fraction, whilst decreasing it in the cytosol fraction. This confirmed that PKC translocation could be followed using this technique. Figure 5 depicts a repre- sentative experiment, which shows that treatment of OK cells with 5 nmol/l C-peptide for 5 min resulted in a two-fold increase in the amount of PKC-α in the membrane fraction compared to the control cells, which had been subjected to a change of media alone (lacking C-peptide). In contrast, the amounts of PKC-ε and -ι isoforms remained unchanged in the membrane fraction after C-peptide stimulation, although membrane translocation of PKC-ε was seen after PMA treatment (Fig. 5a) . Thus, C-peptide specifically translocates PKC-α in OK cells.
C-peptide may elicit its cellular effects by binding to a putative cell membrane receptor coupled to a PTX-sensitive G-protein [16, 17] . To determine whether C-peptide recruited PKC-α to the membrane through such a receptor, OK cells were treated with PTX (100 ng/ml) for 18 h before stimulation with 5 nmol/l C-peptide. PTX pre-treatment resulted in complete inhibition of C-peptide-induced PKC-α translocation (Fig. 6) .
Since the PKC-α isoform is Ca 2+ -dependent, we examined whether the activation of PKC-α was dependent upon extracellular Ca 2+ . Cells were incubated with Ca 2+ -free Krebs Henseleit buffer for 1 h before exposure to C-peptide. As shown in Figure 6 , C-peptide failed to translocate PKC-α in the absence of extracellular Ca 2+ .
Effects of C-peptide on the growth of OK cells.
After demonstrating the ability of C-peptide to activate mitogenic signalling pathways in OK cells, we studied the effect of C-peptide on cell proliferation. As demonstrated in Figure 7a , incubation of OK cells with C-peptide for 24 h resulted in an increase in [ 3 H]-thymidine incorporation. This increase was maximal at 5 nmol/l C-peptide (130±3.5%, compared to non-stimulated controls; n=4). As a positive control, the effect of 10% FCS on proliferation of OK cells was studied and found to increase [ 3 H]-thymidine incorporation by 5 . Effect of C-peptide on PKC-ι, -ε and -α isoform translocation in opossum kidney cells. Serum-starved cells were treated with either 5 nmol/l C-peptide or 1 µmol/l phorbol myristate acetate (PMA) for 5 min. Membrane and cytosol where prepared as described. a. PKC isoforms were detected by western blotting of membrane and cytosol fractions with isoform-specific anti-PKC-ι, -ε and -α antibody. b. The amounts of PKC-α in membrane (black bars) and cytosolic (white bars) fractions were quantified using Scion Image analysis software and results are expressed relative to those of untreated control cells. Data are means ± SEM, n=5. * p<0.05, ** p< 0.01, relative to control Fig. 6 . PKC-α translocation is inhibited by pertussis toxin (PTX) and in Ca 2+ -free medium. Opossum kidney cells were pre-treated with 100 ng/ml PTX for 18 h or incubated in Ca 2+ -free Krebs buffer prior to stimulation with 5 nmol/l C-peptide for 5 min. a. Membrane and cytosol were prepared and PKC-α was detected by western blotting. A representative immunoblot is depicted. b. The amount of PKC-α detected in immunoblots was quantified using Scion Image analysis software. The results are expressed relative to those of untreated control cells that were normalised to a value of 1. White bars: responses of cells in Ca 2+ -containing Krebs buffer (control); black bars: responses of cells in Ca 2+ -free Krebs buffer; hatched bars: responses in cells pre-treated with PTX. Data are means ± SEM, n=4. * p<0.05 relative to controls 370±8% (data not shown). Thus, C-peptide induced a significant increase in OK cell proliferation compared to non-stimulated controls, but this increase was modest compared to that achieved by 10% FCS. In some experiments cells were pre-treated either with PTX for 18 h, or with wortmannin for 30 min before being exposed to C-peptide (Fig. 7b) . Both PTX and wortmannin pre-treatments attenuated the C-peptideinduced proliferation of OK cells.
Discussion
Although C-peptide is important as a surrogate marker of insulin release and hence pancreatic beta cell function, it has for many years been regarded as biologically inert with no significant physiological purpose. In recent years a small number of publications have challenged this view and a growing body of data, derived from studies of animals and humans with diabetes, now supports the idea that C-peptide plays a role in glucose homeostasis, in ameliorating the consequences of hyperglycaemia and in the abrogation of diabetic complications [6, 10, 12] . Despite this accumulating evidence, the concept of C-peptide as a bioactive molecule has yet to gain wide acceptance. Nonetheless, the observation that C-peptide can alter cell function suggests that, like insulin, it may exert endocrine actions and possess signalling activity. Our aim therefore was to establish a repertoire of cell signalling effects induced by C-peptide in a relevant cell line derived from the kidney proximal tubule, a nephron region thought to play a central role in tubulointerstitial injury in diabetes [36, 37] .
Our results demonstrate clear and unambiguous stimulation of a number of key intracellular signalling pathways by C-peptide, but not by its scrambled counterpart, in OK cells with distinct cell functional consequences. Using two different methods, we unequivocally demonstrated stimulation of ERK by typical physiological concentrations of C-peptide [38, 39, 40] in the mid-picomolar to low-nanomolar range. Furthermore, phosphorylation of Akt induced by C-peptide is indicative of PI 3-kinase activation. Although both of these phenomena demonstrate similar rapid kinetics of activation, C-peptide is a more potent activator of ERK than PI-3 kinase. Also the relationship between ERK stimulation and C-peptide concentration is described by a bell-shaped curve, whereas the relationship between C-peptide concentration and ERK stimulation is sigmoidal. There is little evidence that C-peptide signals via more than one receptor, and the explanation of these differences is unclear.
Consistent with the observations of others [13, 15] , we observed C-peptide-evoked increases in [Ca 2+ ] i . In our studies only a minority of cells showed a robust rise in [Ca 2+ ] i , the majority showing modest increases and approximately 10% not showing any response at all. Whilst such heterogeneity of response may reflect heterogeneity in the cell culture population, no such variability was seen in our earlier studies of lysophosphatidic acid-induced Ca 2+ transients in this cell type [32] . In practical terms, however, this variability in the observed Ca 2+ responses limited our ability to dissect the mechanisms underlying C-peptide-induced changes in [Ca 2+ ] i .
Our observation of Ca 2+ -dependent membrane translocation of PKC-α supports the idea that C-peptide activates Ca 2+ signalling in OK cells, providing evidence for the concept that Ca 2+ -dependent pathways play an important role in actions mediated by C-peptide [13, 15, 41] . Robust PKC-α translocation was also observed in response to C-peptide at physiologically relevant low nanomolar concentrations. Abolition of this phenomenon in Ca 2+ -free medium and by PTX indicates that it is mediated via a GPCR and dependent on entry of Ca 2+ into the cell, rather than its release from intracellular stores. The PKC isoforms -ε and -ι were detected by western blotting but did not translocate. Efendiev et al. [42] indicated that OK cells express all the PKC isoforms except γ. In the current study, we did not detect other PKC isoforms in OK cells, and in fact a detailed evaluation of PKC isoforms was not intended. These differences probably relate to problems of antibody specificity and consequent failure to detect opossum PKC isoforms.
A plasma membrane receptor for C-peptide has not yet been identified, and it has been suggested that non-receptor-mediated membrane interactions could explain C-peptide effects [43] . However, the inhibition, by PTX, of C-peptide-stimulated signalling in OK cells implicates a GPCR, coupled to either Gα i or Gα o , in the transduction of these events. Such observations are in agreement with studies demonstrating PTX-sensitive C-peptide binding to kidney cell membranes [18] , and they provide strong support for the existence of a specific C-peptide receptor. Furthermore, the C-peptide concentrations that stimulated signalling in the current studies correlate well with the affinity of the previously described binding sites [18] .
C-peptide-induced ERK activity via Gα i/o coupling receptor suggests a possible involvement of Gβγ. A common ERK stimulatory module involves activation of PI3-kinase by Ras, mediated via Gβγ subunits [44] . However, C-peptide-induced ERK activity was not affected by wortmannin, suggesting that PI3-kinase is not involved in this stimulation. The attenuation of ERK activity by pre-treatment with Ro-31-8820 suggests that C-peptide-induced ERK activity is dependent on PKC in OK cells as proposed by Kitamura et al. [17] for Swiss 3T3 fibroblasts.
Following our observation that C-peptide stimulated kinases with well-described roles in the regulation of growth, proliferation and cell survival [45, 46, 47] , we wished to determine whether C-peptide was a functional mitogen in OK cells. Accordingly, physio- logical concentrations of C-peptide were found to stimulate OK cell proliferation in a manner that was dependent on PI 3-kinase activity and sensitive to PTX. Previous studies reported that similar concentrations of C-peptide are mitogenic for human neuroblastoma cells [48] . This latter finding is compatible with our present results and suggests that ERK is involved in C-peptide-induced cell proliferation. It is, however, difficult to interpret concentration dependency data in OK cells, because proximal tubular cells are active in peptide catabolism. Thus, after the obligate exposure of OK cells to C-peptide for 24 h in [ 3 H]-thymidine incorporation studies, C-peptide concentrations in the culture medium may be considerably lower than those applied at the start of the experiment. Nevertheless, it is tempting to suggest that the absence of this mitogenic effect in diabetes may contribute to the hypertrophic renal growth abnormalities seen in diabetic nephropathy.
The salutary effects of C-peptide observed in patients with diabetes are not paralleled by similar observations in healthy individuals. Moreover, data on C-peptide binding suggest that under normal physiological conditions binding sites may be fully occupied. Thus, reduced C-peptide signalling may only become important in diabetic patients when levels fall or become undetectable. In this situation, one could speculate that balanced interactions between insulin, C-peptide and glucose signalling pathways may be disturbed, leading to the development of diabetic complications.
Some preliminary evidence of cross-talk between insulin and C-peptide has been found. Using L6 rat myoblasts, one group [49] demonstrated that C-peptide inhibits protein tyrosine phosphatase, with associated increases in phosphorylation of the insulin receptor and insulin receptor substrate-1. These findings in myoblasts were subsequently extended to show insulinomimetic C-peptide effects, manifest as induced phosphorylation of glycogen synthase kinase, ERK and p90Rsk [50] . No effect of C-peptide on phosphorylation of Akt was seen in that study, although C-peptide did increase phosphotyrosine-associated PI 3-kinase activity as measured by immune complex in vitro kinase assay. Some synergy was observed between C-peptide and insulin, but only at sub-maximal concentrations.
Taken together, the available data indicate important GPCR-mediated effects of C-peptide at the cellular level. These translate into vital effects on insulin action and glucose homeostasis, when measured at the whole-animal level. The cellular effects of C-peptide are not apparent in all cells investigated, but are clearly present in OK proximal tubular cells. Indeed, we have also demonstrated identical effects in primary cultures of human proximal tubular cells (data not shown). Further studies of the interaction between C-peptide and insulin signalling and the effects of changes in prevailing glucose concentrations will enhance our understanding of glucose metabolism and the pathogenesis of diabetic complications, thereby providing a new impetus for the investigation of C-peptide as a therapeutic agent in the treatment of diabetes mellitus.
